Mertz Larry Michael's Form 4 filing
Accelerate Diagnostics, Inc (AXDX) · filed Apr 5, 2024
- Accession no.
- 0001104659-24-044296
- Filed
- Apr 5, 2024
- Trade date
- Apr 4, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $860.64. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mertz Larry MichaelCIK 0001938051 | Officer (Chief Technology Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 4, 2024 | Common Stock | MOption exerciseAcquired | +2,866 | $0.00F1 | $0 | 55,435 | Direct | |
| Apr 4, 2024 | Common Stock | SSaleDisposed | −978 | $0.88 | −$860.64 | 54,457 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 4, 2024 | Common Stock | MOption exerciseDisposed | −2,866 | $0.00 | $0 | 4,298 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On April 4, 2022, the reporting person was granted a total of 7,164 restricted stock units ("RSUs"), of which 40% vest on April 4, 2024 and the remaining 60% vest on April 4, 2025. Each RSU represents a contingent right to receive one share of the issuer's common stock upon vesting.
Referenced by the price of 1 transaction in Table I.
Remarks
On July 11, 2023, the issuer effected a reverse stock split of its common stock at a ratio of 1-for-10 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, proportionate adjustments were made to the number of shares of the issuer's common stock underlying its outstanding equity awards, warrants and convertible notes, as well as the exercise or conversion price, as applicable. The amounts reported herein (and to be reported in subsequent reports) have been adjusted to reflect the Reverse Stock Split.